Literature DB >> 15846499

Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer.

Hisashi Onodera1, Akira Mori, Satoshi Nagayama, Akihisa Fujimoto, Tsuyoshi Tachibana, Yoshikuni Yonenaga, Tatsuaki Tsuruyama.   

Abstract

BACKGROUND: The selection of resective therapy for colorectal hepatic metastases remains controversial. The aim of this study is to investigate the prognostic factors for patients with resected liver metastases from colorectal cancer by analyzing not only clinicopathological factors but also recent immunohistological markers.
METHODS: Eighty-five patients underwent hepatic resection for metastatic colorectal cancer over the past 20 years. Fas/CD95 expression, microvessel density, and proliferating cell nuclear antigen (PCNA) proliferative activity were assessed with immunohistochemical methods in addition to the clinicopathological factors. Survival analysis was performed using the Kaplan-Meier method and Cox proportional hazards model, both univariately and multivariately.
RESULTS: Univariate and multivariate analyses revealed that the number of metastases, Fas/CD95 expression, and postoperative carcinoembryonic antigen doubling time (CEADT) were significant prognostic indicators, whereas the mode of hepatic resection, chemotherapy, and other clinicopathological factors had no influence on survival. Fas/CD95 index correlated with postoperative CEADT (p=0.039), number of metastases (p=0.018), and survival (p=0.023).
CONCLUSIONS: Our study confirmed the number of metastases and CEADT as prominent prognostic factors after hepatic resection for metastatic colorectal cancer. These two factors reflect the degree of Fas/CD95 signaling rather than angiogenesis or cancer growth rate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846499     DOI: 10.1007/s00384-004-0708-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  46 in total

1.  Angiogenesis of liver metastases: role of sinusoidal endothelial cells.

Authors:  P Gervaz; B Scholl; C Mainguene; S Poitry; M Gillet; S Wexner
Journal:  Dis Colon Rectum       Date:  2000-07       Impact factor: 4.585

2.  Resistance to apoptosis is increased during metastatic dissemination of colon cancer.

Authors:  L Oliver; S Cordel; I Barbieux; M T LeCabellec; K Meflah; M Grégoire; F M Vallette
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

3.  Hepatic resection for metastases from colorectal carcinoma--a survival analysis.

Authors:  G R Jatzko; P H Lisborg; H M Stettner; M H Klimpfinger
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

4.  Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection.

Authors:  Norihiro Kokudo; Yoshio Miki; Sachiko Sugai; Akio Yanagisawa; Yo Kato; Yoshihiro Sakamoto; Junji Yamamoto; Toshiharu Yamaguchi; Tetsuichiro Muto; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2002-07

Review 5.  Apoptosis. Its significance in cancer and cancer therapy.

Authors:  J F Kerr; C M Winterford; B V Harmon
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

6.  Microvessel quantitation and prognosis in invasive breast carcinoma.

Authors:  S Bosari; A K Lee; R A DeLellis; B D Wiley; G J Heatley; M L Silverman
Journal:  Hum Pathol       Date:  1992-07       Impact factor: 3.466

7.  Resection of hepatic metastases from colorectal cancer.

Authors:  M A Adson; J A van Heerden; M H Adson; J S Wagner; D M Ilstrup
Journal:  Arch Surg       Date:  1984-06

8.  Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma.

Authors:  K Kawamoto; H Onodera; S Kan; S Kondo; M Imamura
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

9.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

10.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  5 in total

1.  Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.

Authors:  Nadezhda V Koshkina; Krithi Rao-Bindal; Eugenie S Kleinerman
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

Review 2.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

3.  Role of lifeguard β-isoform in the development of breast cancer.

Authors:  Nadjib Dastagir; Andrea Lazaridis; Khaled Dastagir; Kerstin Reimers; Peter M Vogt; Vesna Bucan
Journal:  Oncol Rep       Date:  2014-07-25       Impact factor: 3.906

4.  Prognostic value of the Fas/Fas ligand system in breast cancer.

Authors:  Marek Bębenek; Danuta Duś; Joanna Koźlak
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29

Review 5.  Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis.

Authors:  William Torén; Daniel Ansari; Roland Andersson
Journal:  Cancer Cell Int       Date:  2018-12-27       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.